Luis
Bujanda Fernández de Piérola
Publicaciones (510) Publicaciones de Luis Bujanda Fernández de Piérola
2024
-
A Novel, Noninvasive Method to Diagnose Active Eosinophilic Esophagitis, Combining Clinical Data and Oral Cavity RNA Levels
Clinical Gastroenterology and Hepatology
-
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death
Scientific reports, Vol. 14, Núm. 1, pp. 3000
-
CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions
Gastric Cancer, Vol. 27, Núm. 4, pp. 747-759
-
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry
Therapeutic Advances in Gastroenterology, Vol. 17
-
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259
-
Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance
American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654
-
Enfermedades del estómago y del duodeno.
Medicina interna (Elsevier España), pp. 96-129
-
Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry
Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264
-
Gene content, phage cycle regulation model and prophage inactivation disclosed by prophage genomics in the Helicobacter pylori Genome Project
Gut Microbes, Vol. 16, Núm. 1
-
Human Colonic Organ Culture Reveals XPO1-Independent Ability of Salvianolic Acid to Reduce Ulcerative Colitis–Related Inflammation
Gastro Hep Advances
-
Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes
Journal of Crohn's and Colitis, Vol. 18, Núm. 3, pp. 349-359
-
Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg)
Helicobacter, Vol. 29, Núm. 4
-
Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588
-
Non-specific protection against severe COVID-19 associated to typhoid fever and DTP vaccination
Heliyon, Vol. 10, Núm. 9
-
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU
Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853
-
Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management
United European Gastroenterology Journal, Vol. 12, Núm. 1, pp. 122-138
-
Serum DNA methylome of the colorectal cancer serrated pathway enables non-invasive detection
Molecular Oncology, Vol. 18, Núm. 11, pp. 2696-2713
-
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290
-
Stratified analyses refine association between TLR7 rare variants and severe COVID-19
Human Genetics and Genomics Advances, Vol. 5, Núm. 4
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5